Events

Recall of KYPHX HV-R - HIGH VISCOSITY RADIOPAQUE BONE CEMENT

According to Health Canada (via FOI), this recall involved a device in Canada that was produced by MEDTRONIC SPINE LLC.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    51383
  • Event Risk Class
    III
  • Event Initiated Date
    2008-05-12
  • Event Country
    Canada
  • Event Source
    HC
  • Notes / Alerts
    Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
  • Extra notes in the data
  • Reason
    As a result of a packaging error a small number of units of one lot may have been shipped with either no instructions for use (ifu) or the incorrect us version of the ifu for the hv-r bone cement device.

Device

KYPHX HV-R - HIGH VISCOSITY RADIOPAQUE BONE CEMENT
  • Model / Serial
    Model Catalog: C01B (Lot serial: J7102403)
  • Product Description
    KYPHX HV-R BONE CEMENT W/ KYPHON MIXER
  • Manufacturer
    MEDTRONIC SPINE LLC

Manufacturer

MEDTRONIC SPINE LLC
  • Manufacturer Address
    SUNNYVALE
  • Manufacturer Parent Company (2017)
    Medtronic plc
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    HC